Pharma Equity Group AS (OCSE:PEG) Total Liabilities : kr16.73 Mil (As of Dec. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Total Liabilities?

Pharma Equity Group AS's Total Liabilities for the quarter that ended in Dec. 2024 was kr16.73 Mil.

Pharma Equity Group AS's quarterly Total Liabilities increased from Jun. 2024 (kr50.74 Mil) to Sep. 2024 (kr60.87 Mil) but then declined from Sep. 2024 (kr60.87 Mil) to Dec. 2024 (kr16.73 Mil).

Pharma Equity Group AS's annual Total Liabilities increased from Dec. 2022 (kr25.03 Mil) to Dec. 2023 (kr42.40 Mil) but then declined from Dec. 2023 (kr42.40 Mil) to Dec. 2024 (kr16.73 Mil).

Pharma Equity Group AS Total Liabilities Historical Data

The historical data trend for Pharma Equity Group AS's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group AS Total Liabilities Chart

Pharma Equity Group AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

23.30

21.08

25.03

42.40

16.73

Pharma Equity Group AS Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															42.40	46.52	50.74	60.87	16.73

Pharma Equity Group AS Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Pharma Equity Group AS's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.631	+	(8.1	+	1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	16.73

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	65.606	-	48.875
	=	16.73

Pharma Equity Group AS's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	8.631	+	(8.1	+	1.7763568394003E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	16.73

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	65.606	-	48.875
	=	16.73

Pharma Equity Group AS Total Liabilities Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .